Suppr超能文献

右美托咪定:新生儿镇静与疼痛控制模式的转变

Dexmedetomidine: Shifting Paradigms in Neonatal Sedation and Pain Control.

作者信息

Chan Kok Joo, Bolisetty Srinivas

机构信息

Newborn Care Centre, Royal Hospital for Women, Sydney, NSW 2031, Australia.

Discipline of Paediatrics & Child Health, University of New South Wales, Sydney, NSW 2031, Australia.

出版信息

Children (Basel). 2025 Mar 30;12(4):444. doi: 10.3390/children12040444.

Abstract

BACKGROUND

Newborns, including preterm infants, are capable of responding to pain. Recurrent pain exposure is associated with suboptimal motor development, cognitive impairments, abnormal brain growth, and maladapted nociceptive reactions.

PROBLEM

Current agents, primarily opioids and benzodiazepines, raise major concerns due to their adverse effects, including insufficient sedation or analgesia, withdrawal, depressed respiratory effort, tolerance, and occasional paradoxical agitation. Commonly used drugs such as midazolam and morphine have been shown to induce neuroapoptosis and neurodevelopmental abnormalities in animal studies. Evaluation-Dexmedetomidine: As a specific alpha-2 adrenergic agonist, dexmedetomidine causes a significantly lower reduction in breathing effort. It has over 800 times greater affinity for alpha-2 receptors compared to alpha-1 receptors. Common side effects include bradycardia and hypotension. Prolonged use may necessitate a transition to clonidine during the weaning process. Dexmedetomidine can be administered intravenously as a bolus or infusion or intranasally. Indications include sedation and analgesia for mechanical ventilation, therapeutic hypothermia, procedural premedication, and as an adjunct to inhalational anesthesia and nerve-blocking agents. Research across varying age groups has demonstrated that dexmedetomidine shortens periods of invasive ventilation and decreases the need for other sedatives. Neonatal studies suggest that dexmedetomidine may help accelerate the achievement of full enteral feeds and can be safely administered within specific dosage ranges without causing significant adverse events that would necessitate abrupt discontinuation.

CONCLUSIONS

Dexmedetomidine can be used alone or in combination with other agents. By increasing the use of dexmedetomidine, it is possible to reduce the dosage of concurrent medications, thereby minimizing the risk of complications while still achieving the desired sedation and analgesia.

摘要

背景

新生儿,包括早产儿,能够对疼痛做出反应。反复暴露于疼痛与运动发育欠佳、认知障碍、脑生长异常以及伤害性反应适应不良有关。

问题

目前的药物,主要是阿片类药物和苯二氮䓬类药物,因其不良反应引发了重大担忧,包括镇静或镇痛不足、戒断反应、呼吸努力受抑制、耐受性以及偶尔出现的矛盾性激越。在动物研究中,常用药物如咪达唑仑和吗啡已被证明会诱导神经细胞凋亡和神经发育异常。评估——右美托咪定:作为一种特异性α-2肾上腺素能激动剂,右美托咪定引起的呼吸努力降低明显较少。与α-1受体相比,它对α-2受体的亲和力高出800多倍。常见副作用包括心动过缓和低血压。长期使用可能在撤药过程中需要转换为可乐定。右美托咪定可以静脉推注或输注给药,也可鼻内给药。适应证包括用于机械通气的镇静和镇痛、治疗性低温、手术前用药以及作为吸入麻醉和神经阻滞药物的辅助用药。针对不同年龄组的研究表明,右美托咪定可缩短有创通气时间并减少对其他镇静剂的需求。新生儿研究表明,右美托咪定可能有助于加快实现完全经口喂养,并且可以在特定剂量范围内安全给药,而不会引起需要突然停药的重大不良事件。

结论

右美托咪定可单独使用或与其他药物联合使用。通过增加右美托咪定的使用,可以减少同时使用药物的剂量,从而在仍能实现所需镇静和镇痛的同时将并发症风险降至最低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cd5/12025972/52313b4ab857/children-12-00444-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验